145 results match your criteria: "Prostatic Stromal Sarcoma"
Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival.
Ann Surg Oncol
December 2024
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Article Synopsis
- This study analyzed the clinicopathologic characteristics and treatment patterns of adult prostate sarcoma patients using data from the Surveillance, Epidemiology, and End Results database between 2004 and 2020.
- Among 125 patients, the most common subtype was leiomyosarcoma (36%), with rhabdomyosarcoma (14%) being more likely to present at a metastatic stage compared to other types.
- The overall median survival was 27 months, with treatment approaches differing significantly based on the subtype; metastatic disease was linked to higher mortality rates, while stromal sarcoma had a lower overall mortality risk.
Adult prostate stromal sarcoma: Desmoplastic small round cell tumor.
Asian J Surg
December 2024
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. Electronic address:
Magnetic resonance imaging presentation of prostatic stromal sarcoma.
Radiol Case Rep
October 2024
Department of Radiology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.
Article Synopsis
- Prostatic stromal sarcoma (PSS) is a rare type of cancer that usually affects younger people.
- There isn't much information about how PSS looks on imaging tests like MRI, even though doctors know a lot about how it behaves in the body.
- This study looks at MRI images, tissue samples, and how to tell PSS apart from another type of prostate cancer called prostate cancer (PCA).
Primary Prostatic Stromal Sarcoma on 18 F-PSMA PET/CT.
Clin Nucl Med
October 2024
Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, China.
Article Synopsis
- Primary prostatic stromal sarcoma is a very rare type of cancer that affects the prostate gland.
- The normal blood test for PSA was seen in a 23-year-old man who had this rare cancer.
- After receiving chemotherapy, the cancer in his prostate got better, and the spots in his liver disappeared too.
Prostate stromal sarcoma mimicking benign prostate hyperplasia: A case report.
Int J Surg Case Rep
September 2024
Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara - Haji Adam Malik General Hospital, Medan, Indonesia.
Article Synopsis
- * A 45-year-old man showed symptoms like weight loss and urinary problems and was initially misdiagnosed with a less serious condition.
- * To diagnose this aggressive cancer correctly, doctors need to do special tests, like looking at tissue samples, because it can be confused with other prostate issues.
Analysis of three primary prostatic sarcoma cases and literature review.
Prostate
September 2024
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- * Doctors reviewed their medical records and found that two had stromal sarcoma and one had spindle cell sarcoma, which are types of high-grade cancers.
- * The researchers concluded that this cancer is very rare and usually doesn't have a good outcome, so early detection and treatment are super important, but recurrence is still a big risk even after treatment.
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
Ann Oncol
July 2024
INSERM U981, Gustave Roussy, Villejuif; Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre. Electronic address:
Background: Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice.
Methods: The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility.
Results: As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer.
Prostatic stromal tumor of uncertain malignant potential: a case report and literature review.
J Int Med Res
May 2024
Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen PKU-HKUST Medical Center, Shenzhen, China.
Article Synopsis
- * A guy in his early 40s had STUMP but didn't have high PSA levels; he had painful symptoms for over 7 months before doctors figured it out.
- * After an MRI showed something unusual and a biopsy confirmed he had mucinous liposarcoma, he had surgery and the doctors learned more about diagnosing and treating this rare condition.
A radiation-related second primary gastrointestinal stromal tumor in the bladder.
Curr Urol
December 2023
Department of Urology, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital, Kawasaki, Japan.
Article Synopsis
- A 69-year-old man got radiation therapy for prostate cancer and then developed a bladder tumor seven years later.
- Doctors removed the tumor, and tests showed it was a rare type of cancer called spindle cell sarcoma.
- The tumor was linked to his previous radiation treatment, making this a unique case of another cancer happening because of the first treatment.
A case report of primary mesenchymal sarcoma of the prostate and the thoughts on its treatment.
Asian J Surg
November 2023
Department of Robotic Minimally Invasive Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, 610072, China. Electronic address:
Introduction: Prostatic stromal sarcoma is an extremely rare malignancy of the prostate with a poor prognosis.
Case Presentation: A 65-year-old man presented with dyschezia, and computed tomography showed a large prostate mass. The diagnosis was prostate stromal sarcoma by transrectal needle biopsy.
Prostatic stromal sarcoma: A case report and literature review.
Radiol Case Rep
September 2023
Department of Radiology, Pham Ngoc Thach University of Medicine, 2 Duong Quang Trung Ward 12 District 10, Ho Chi Minh City, 700000, Vietnam.
Article Synopsis
- Stromal sarcoma of the prostate is really rare, which means not many people have it.
- A 43-year-old man went to the hospital because he had trouble urinating, and doctors found out he had this type of cancer.
- After surgery, doctors discovered the cancer was more serious than they first thought, and the article wants to teach others about how to recognize this rare disease.
Prostatic stromal sarcoma: Report of a rare case in a young male and review of the literature.
Int J Surg Case Rep
May 2023
Department of Pathology, Ospedale del Mare, Naples, NA, Italy.
Article Synopsis
- A 31-year-old man had problems with urination and was found to have a rare type of prostate cancer called prostatic stromal sarcoma after undergoing tests.
- Although doctors tried to help him with chemotherapy, he sadly passed away 8 months later because he didn't want surgery.
- This case is important because it shows how unusual cancers can be tricky to diagnose and treat, and doctors need to remember these rare types when dealing with prostate problems.
A rare Prostatic Stromal Tumor - Stromal Tumor of Uncertain Malignant Potential (STUMP) and Prostatic Stromal Sarcomas (PSS) as cultural sexual health problem in a young adult: A case report.
Urol Case Rep
May 2023
Hasanuddin University, School of Medicine, Indonesia.
Article Synopsis
- Stromal prostatic tumors are rare and include types called STUMP and PSS, which can affect sexual health, like causing Erectile Dysfunction (ED).
- A 29-year-old man had issues with urination and blood in his urine, leading to a diagnosis of a prostatic tumor after imaging tests.
- The doctors found that his tumor changed from STUMP to PSS after surgery, and his Erection Hardness Score dropped from four points to two after the operation.
Cabozantinib for the treatment of solid tumors: a systematic review.
Ther Adv Med Oncol
July 2022
Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Article Synopsis
- * A systematic review was conducted, evaluating 114 studies that involved cabozantinib monotherapy for solid tumors, focusing on clinical outcomes and safety, while excluding small and combination therapy studies.
- * The review revealed that cabozantinib has been studied for numerous other cancers beyond its approved uses, with common side effects being hypertension, diarrhea, and fatigue, supporting its efficacy in treating solid tumors.
Detection of relatively poor but definitive blood supply in prostate stromal sarcoma using transrectal ultrasonography with superb microvascular imaging.
Int Cancer Conf J
July 2022
Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-Hirokoji, Kyoto, 602-8566 Japan.
Article Synopsis
- A 23-year-old man with macrohematuria and hematospermia was found to have a 30×25 mm tumor in the right peripheral zone of his prostate through MRI, suggesting a rare prostate tumor.
- Transrectal ultrasound (TRUS) revealed a well-defined tumor, and while standard color Doppler imaging missed any blood flow, superb microvascular imaging (SMI) detected low-velocity blood flow within the tumor.
- After a TRUS-guided biopsy confirmed the diagnosis of prostate stromal sarcoma, the patient underwent extensive surgery, and this case highlights the potential of SMI in identifying blood flow in rare malignant tumors.
Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.
Mod Pathol
July 2022
Department of Anatomical Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Article Synopsis
- NTRK-rearranged mesenchymal tumors mainly affect soft tissues in kids but can rarely occur in adults too.
- In a study of 7 adult patients (ages 18-53), researchers looked at tumors in different body parts like the lung, heart, and prostate that had special genetic changes.
- These tumors had different appearances, some were more serious than others, and while they mostly tested positive for certain proteins, it's important to confirm their diagnosis with more detailed genetic tests.
ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications.
Diagn Pathol
February 2022
Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Article Synopsis
- - The **SWItch Sucrose Non-Fermentable (SWI/SNF)** complex helps stop tumors from growing, and if parts of it are damaged, it can lead to cancer. One important part, **ARID1A**, is often messed up in tumors, especially in certain cancers. - A 58-year-old man had problems urinating and was found to have a large tumor in his prostate. After trying chemotherapy, his tumor grew bigger, and he needed surgery to remove it. - Doctors found that his tumor had unusual **rhabdoid cells**, which are a specific shape, and showed signs of being very aggressive. Tests confirmed that his tumor had **missing ARID1A** pieces, linking it
A case of incidental STUMP discovery in a patient with concurrent prostatic adenocarcinoma.
J Surg Case Rep
December 2021
Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Stromal tumours of the prostate are exceedingly rare, often presenting in patients in their fifth decade of life. They are classified as either stromal sarcomas, or stromal tumours of uncertain malignant potential (STUMP), the latter of which is known to have diverse clinical behaviour and thus surgical excision is often warranted. We present a case of a 71-year-old male, initially worked up by his family doctor due to mild obstructive voiding symptoms.
View Article and Find Full Text PDFSafety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
March 2022
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Molibresib is a new medication that blocks certain proteins and is taken by mouth. In a study, they found that taking 75 mg once a day is the best dose to try for different types of cancer.
- The study looked at how safe the medicine is and how well it works against different cancers like testicular cancer and breast cancer, finding some side effects like low blood platelets and nausea that happened to many patients.
- Although some patients showed a decrease in tumor size, the overall results weren’t good enough for all cancers to be considered a strong success, and the researchers think combining Molibresib with other treatments might work better.
Low-grade endometrial stromal sarcoma-like tumors in male with JAZF1 gene fusions.
Genes Chromosomes Cancer
February 2022
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Article Synopsis
- Low-grade endometrial stromal sarcoma (ESS) is a type of cancer usually found in women, but two new cases occurred in men, which is very rare.
- These cases showed special genetic changes (called fusions) that are linked to the disease, like JAZF1-GLI3 and JAZF1-PHF1.
- The men had tumors that looked similar under a microscope to the ones found in women, and one patient had a recurrence of his cancer two years after surgery.
Reexamining the molecular findings in specialized stromal tumors of the prostate.
Mod Pathol
November 2021
Departments of Pathology, The Johns Hopkins Hospital, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
Mod Pathol
September 2021
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- This study looked at different types of tumors in the prostate that may come from special cells in the tissue.
- Researchers used advanced DNA and RNA testing on 25 tumors, finding many had genetic changes.
- The findings suggest these tumors are very different from each other and may not fit into one specific type, leading to questions about how they should be diagnosed.
18F-FDG PET/CT Imaging of Prostate Stromal Tumor of Uncertain Malignant Potential.
Clin Nucl Med
April 2021
From the Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
Article Synopsis
- A 79-year-old man had trouble urinating and a high test result for prostate problems.
- An MRI showed his prostate was swollen, but it couldn’t confirm if there was cancer.
- A biopsy (a test where they took a piece of tissue) showed he had a type of tumor that could be cancerous and that it spread to his spine and other bones.
Contrast-enhanced ultrasound diagnosis of prostatic sarcoma: Two case reports.
Medicine (Baltimore)
January 2021
Department of Ultrasound Medicine, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia, 010017, China.
Article Synopsis
- * Two patients, one 64 years old with PS and one 36 years old with Ewing's sarcoma, were checked using a special ultrasound before their surgeries.
- * The older patient had their prostate removed while the younger patient received chemotherapy and radiation; the ultrasound showed the cancer spreading in the prostate, and it proved to be a useful and safe way to help diagnose PS.